Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV), Veeva Systems (VEEV) and Janux Therapeutics Inc (JANX)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Elevance Health (ELV – Research Report), Veeva Systems (VEEV – Research Report) and Janux Therapeutics Inc (JANX – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Elevance Health (ELV)
In a report issued on March 3, Stephen Baxter from Wells Fargo maintained a Buy rating on Elevance Health, with a price target of $391.00. The company’s shares closed last Wednesday at $291.45.
According to TipRanks.com, Baxter is a 1-star analyst with an average return of
Currently, the analyst consensus on Elevance Health is a Moderate Buy with an average price target of $389.07, representing a 36.8% upside. In a report issued on March 3, Barclays also maintained a Buy rating on the stock with a $393.00 price target.
See today’s best-performing stocks on TipRanks >>
Veeva Systems (VEEV)
In a report released today, Ryan MacDonald from Needham reiterated a Buy rating on Veeva Systems, with a price target of $270.00. The company’s shares closed last Wednesday at $188.48.
According to TipRanks.com, MacDonald has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Veeva Systems is a Moderate Buy with an average price target of $257.36, implying a 38.0% upside from current levels. In a report issued on February 19, TipRanks – xAI also upgraded the stock to Buy with a $200.00 price target.
Janux Therapeutics Inc (JANX)
In a report issued on March 3, Karina Rabayeva from Truist Financial reiterated a Buy rating on Janux Therapeutics Inc, with a price target of $80.00. The company’s shares closed last Wednesday at $14.35.
According to TipRanks.com, Rabayeva is ranked #11008 out of 12134 analysts.
Currently, the analyst consensus on Janux Therapeutics Inc is a Strong Buy with an average price target of $54.00, implying a 299.4% upside from current levels. In a report issued on February 17, William Blair also maintained a Buy rating on the stock.
